Director Intellectual Property
Tango Therapeutics
Director Intellectual Property
Tango Therapeutics
Develops synthetic-lethality cancer therapies
Company Overview
Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.
Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer.
This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing.
The Tango labs and offices are located at 201 Brookline Avenue, in the Fenway area of Boston, Massachusetts.
Summary:
We are seeking a highly skilled, motivated attorney to join our team as Director, Intellectual Property. Reporting to the General Counsel, this role will lead Tango’s intellectual property function and manage all facets of IP through the various stages of product development. This role will implement the company’s intellectual property strategy in the oncology space, counsel internal clients, manage patent filing and prosecution, review publications, track regulatory exclusivities for each product, perform freedom to operate analysis, handle trademark prosecution, and oversee IP litigation. Further, this role will work closely with the Business Development team to support strategic transactions. This role offers a broad range of responsibilities and significant growth opportunities in an exciting and growing company.
Responsibilities:
Education & Experience
We are an equal opportunity employer and value diversity at our company.
We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
Salary range 198400 - 297600 USD
Develops synthetic-lethality cancer therapies
Tango Therapeutics develops cancer medicines by leveraging synthetic lethality to selectively kill cancer cells while sparing healthy cells. Its approach focuses on creating drugs that exploit interactions between gene pairs, aiming for targeted therapies that spare normal tissue. The company advances its treatments through a strong R&D program and collaborates with larger pharmaceutical partners, such as Gilead Sciences, to co-develop therapies and accelerate commercialization. Revenue comes from these partnerships and funding rounds like its Series B. Tango differentiates itself with a dedicated emphasis on genetically targeted cancer therapies, a robust pipeline, and leadership that guides strategic collaborations. The company’s goal is to bring next-generation, genetically targeted immunotherapies to market, improving outcomes for cancer patients by precisely targeting tumor biology.
Explore more opportunities at Tango Therapeutics